Determinants of normoglycemia and contribution to cardiovascular risk factors in a Chinese population: The Hong Kong Cardiovascular Risk Factor Study

2006 ◽  
Vol 29 (6) ◽  
pp. 528-535 ◽  
Author(s):  
G. Neil Thomas ◽  
◽  
S. M. McGhee ◽  
C. M. Schooling ◽  
S. Y. Ho ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Hong Kong ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Cardiovascular Risk Factor ◽  
Chinese Population ◽  
Risk Factor Study ◽  
Factor Study

Impact of sex-specific body composition on cardiovascular risk factors: the Hong Kong Cardiovascular Risk Factor Study

Metabolism ◽  
2006 ◽  
Vol 55 (5) ◽  
pp. 563-569 ◽  
Author(s):  
G. Neil Thomas ◽  
Sarah M. McGhee ◽  
Mary Schooling ◽  
Sai Yin Ho ◽  
Karen S.L. Lam ◽  
...  
Keyword(s):  
Risk Factors ◽  
Body Composition ◽  
Risk Factor ◽  
Hong Kong ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Cardiovascular Risk Factor ◽  
Risk Factor Study ◽  
Factor Study

scholarly journals Metabolic syndrome increases all-cause and vascular mortality: the Hong Kong Cardiovascular Risk Factor Study

2007 ◽  
Vol 66 (5) ◽  
pp. 666-671 ◽  
Author(s):  
G. Neil Thomas ◽  
C. Mary Schooling ◽  
Sarah M. McGhee ◽  
Sai-Yin Ho ◽  
Bernard M. Y. Cheung ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Risk Factor ◽  
Hong Kong ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factor ◽  
Risk Factor Study ◽  
Factor Study ◽  
Vascular Mortality

scholarly journals Development of hypertension over 6 years in a birth cohort of young middle-aged men: the Cardiovascular Risk Factor Study in southern Sweden (CRISS)

2002 ◽  
Vol 252 (1) ◽  
pp. 21-26 ◽  
Author(s):  
K. M. HENRIKSSON ◽  
U. LINDBLAD ◽  
B. GULLBERG ◽  
B. AGREN ◽  
P. NILSSON-EHLE ◽  
...  
Keyword(s):  
Risk Factor ◽  
Cardiovascular Risk ◽  
Birth Cohort ◽  
Cardiovascular Risk Factor ◽  
Southern Sweden ◽  
Middle Aged ◽  
Risk Factor Study ◽  
Factor Study

scholarly journals Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

2020 ◽  
Vol 79 (11) ◽  
pp. 1400-1413 ◽  
Author(s):  
Philip Mease ◽  
Christina Charles-Schoeman ◽  
Stanley Cohen ◽  
Lara Fallon ◽  
John Woolcott ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Risk Factors ◽  
Risk Factor ◽  
Cardiovascular Risk ◽  
Psoriatic Arthritis ◽  
Cardiovascular Risk Factors ◽  
Cardiovascular Risk Factor ◽  
Ad Hoc ◽  
Thromboembolic Events ◽  
The Us

ObjectivesTofacitinib is a Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis, and has been investigated in psoriasis (PsO). Routine pharmacovigilance of an ongoing, open-label, blinded-endpoint, tofacitinib RA trial (Study A3921133; NCT02092467) in patients aged ≥50 years and with ≥1 cardiovascular risk factor identified a higher frequency of pulmonary embolism (PE) and all-cause mortality for patients receiving tofacitinib 10 mg twice daily versus those receiving tumour necrosis factor inhibitors and resulted in identification of a safety signal for tofacitinib. Here, we report the incidence of deep vein thrombosis (DVT), PE, venous thromboembolism (VTE; DVT or PE) and arterial thromboembolism (ATE) from the tofacitinib RA (excluding Study A3921133), PsA and PsO development programmes and observational studies. Data from an ad hoc safety analysis of Study A3921133 are reported separately within.MethodsThis post-hoc analysis used data from separate tofacitinib RA, PsO and PsA programmes. Incidence rates (IRs; patients with events per 100 patient-years’ exposure) were calculated for DVT, PE, VTE and ATE, including for populations stratified by defined baseline cardiovascular or VTE risk factors. Observational data from the US Corrona registries (including cardiovascular risk factor stratification), IBM MarketScan research database and the US FDA Adverse Event Reporting System (FAERS) database were analysed.Results12 410 tofacitinib-treated patients from the development programmes (RA: n=7964; PsO: n=3663; PsA: n=783) were included. IRs (95% CI) of thromboembolic events among the all tofacitinib cohorts’ average tofacitinib 5 mg and 10 mg twice daily treated patients for RA, respectively, were: DVT (0.17 (0.09–0.27) and 0.15 (0.09–0.22)); PE (0.12 (0.06–0.22) and 0.13 (0.08–0.21)); ATE (0.32 (0.22–0.46) and 0.38 (0.28–0.49)). Among PsO patients, IRs were: DVT (0.06 (0.00–0.36) and 0.06 (0.02–0.15)); PE (0.13 (0.02–0.47) and 0.09 (0.04–0.19)); ATE (0.52 (0.22–1.02) and 0.22 (0.13–0.35)). Among PsA patients, IRs were: DVT (0.00 (0.00–0.28) and 0.13 (0.00–0.70)); PE (0.08 (0.00–0.43) and 0.00 (0.00–0.46)); ATE (0.31 (0.08–0.79) and 0.38 (0.08–1.11)). IRs were similar between tofacitinib doses and generally higher in patients with baseline cardiovascular or VTE risk factors. IRs from the overall Corrona populations and in Corrona RA patients (including tofacitinib-naïve/biologic disease-modifying antirheumatic drug-treated and tofacitinib-treated) with baseline cardiovascular risk factors were similar to IRs observed among the corresponding patients in the tofacitinib development programme. No signals of disproportionate reporting of DVT, PE or ATE with tofacitinib were identified in the FAERS database.ConclusionsDVT, PE and ATE IRs in the tofacitinib RA, PsO and PsA programmes were similar across tofacitinib doses, and generally consistent with observational data and published IRs of other treatments. As expected, IRs of thromboembolic events were elevated in patients with versus without baseline cardiovascular or VTE risk factors, and were broadly consistent with those observed in the Study A3921133 ad hoc safety analysis data, although the IR (95% CI) for PE was greater in patients treated with tofacitinib 10 mg twice daily in Study A3921133 (0.54 (0.32–0.87)), versus patients with baseline cardiovascular risk factors treated with tofacitinib 10 mg twice daily in the RA programme (0.24 (0.13–0.41)).

scholarly journals Cardiovascular risk factors in chronic renal failure patient at Soavinandriana Hospital Antananarivo

2020 ◽  
Vol 8 (7) ◽  
pp. 2622
Author(s):  
Lucas Z. Randimbinirina ◽  
Fanomezantsoa H. Randrianandrianina ◽  
Tsirimalala Rajaobelison ◽  
Jean Claude A. Rakotoarisoa ◽  
Agnes M. L. Ravalisoa
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Renal Failure ◽  
Risk Factor ◽  
Cardiovascular Risk ◽  
Chronic Renal Failure ◽  
Cardiovascular Diseases ◽  
Cardiovascular Risk Factors ◽  
Cardiovascular Risk Factor ◽  
High Cardiovascular Risk

Background: Cardiovascular disease (CVD) is the primary cause of morbidity and premature mortality in chronic kidney disease (CKD). The aim of this study was to assess the frequency of cardiovascular disease and cardiovascular risk in haemodialysis population for chronic kidney disease.Methods: This was a retrospective and descriptive study for a period of 4 years from January 2016 to December 2019, performed at hemodialysis unit in Soavinandriana Hospital Center Antananarivo, including all patients, following regular hemodialysis for chronic renal failure. Demographic data, cardiovascular disease, cardiovascular risk factors, aetiology of nephropathy, haemoglobin <11 g/dl, phosphocalcic metabolism disorders and uricemia were analyzed.Results: Seventy-six patients were recorded, including 46 males (60.52%) and were women (39.47%). The average age was 59.98 years old. The risk factors of cardiovascular disease were smoking (22.36%), diabetes mellitus (46.05%), high blood pressure (71.05%), dyslipidemia (47.36%) and obesity (11.84%). Fifty-eight patients (76.31%) had a high cardiovascular risk factor. Seventy patients (22.36%) had had a history of cardiovascular diseases. Fifty-nine patients had a haemoglobin concentration under 11 g/dl (77.63%). There were 23 cases of hypocalcemia (30.26%), 22 cases of hyperphosphatemia (28.94%) and 37 cases of hyperuricemia (48.68%).Conclusions: There was a high cardiovascular risk factor in this study population. Early detection of cardiovascular diseases should be done in patients who have a high-risk factor of cardiovascular disease to decrease the mortality rate in chronic kidney diseases population. The appropriate management of modifiable risk factors is important to improve the survival of this study patients.

scholarly journals Hypertriglyceridemic-Waist Phenotype is Strongly Associated With Cardiovascular Risk Factor Clustering In Chinese adolescents

2021 ◽  
Author(s):  
Rongrong Cai ◽  
Jinyu Zhou ◽  
Lin Bai ◽  
Yangyang Dong ◽  
Wenqing Ding
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Cardiovascular Risk Factor ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Hypertriglyceridemic Waist ◽  
Gender And Age

Abstract There is limited research on the relationship between the Hypertriglyceridemic-waist (HTW) phenotype and cardiovascular risk factors (CVRFs) in adolescents, and its association with cardiovascular risk factor clustering (CVRFC) is unclear. The aim of this study was to examine the association between HTW phenotype and CVRFs and CVRFC in adolescents. A total of 1478 adolescents aged 12-18 years were classified into normal triglyceride normal waist (NTNW, 66.4%), hypertriglyceridemia (HTG, 5.5%), enlarged waist (EW, 22.2%) and hypertriglyceridemia-waist (HTW, 5.8%) according to whether triglycerides (TG)≥1.47 mmol/L and waist circumference (WC) ≥90th percentile by gender and age. CVRFs in this study included elevated blood pressure(BP), impaired fasting glucose(IFG), high total cholesterol(TC), low high-density lipoprotein cholesterol (HDL-C), and high low-density lipoprotein cholesterol(LDL-C). After adjusting for gender and age, the HTW phenotype had a higher risk of Elevated BP, High TC, Low HDL-C and High LDL-C compared to the NTNW phenotype(the OR and 95% CI were 6.00 (3.79-9.52), 4.58 (2.68-7.83), 4.21 (2.44-7.26) and 6.15 (3.39-11.14), respectively). And the HTW phenotype increased the risk of CVRFC ≥ 2 and CVRFC ≥ 3 compared to the NTNW phenotype, the OR and 95% CI were 6.64 (4.08-10.80) and 11.74 (5.95-23.13), respectively. And similar results were obtained for both sexes when stratified by gender. The area under the ROC curve (AUC) for TG combining WC in the prediction of the CVRFC ≥ 2 and CVRFC ≥ 3 were 0.690 (0.651-0.728) and 0.697 (0.659-0.734) in boys, and the AUC were 0.684 (0.647-0.722) and 0.695 (0.657-0.732) for girls(all P<0.01), which were higher than TG or WC alone. These results revealed that the HTW phenotype is closely associated with cardiovascular risk factors clustering, and TG combining WC performed better than TG or WC alone in detecting cardiovascular risk factor clustering in both genders.

scholarly journals Cardiovascular Risk Factors in Children

2021 ◽  
Author(s):  
Mirjam Močnik ◽  
Nataša Marčun Varda
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Cardiovascular Risk Factor ◽  
Pediatric Population ◽  
Adult Life ◽  
Developed Countries ◽  
Primordial Prevention ◽  
Obesity Epidemic

Cardiovascular morbidity and mortality are still increasing in developed countries with emphasis on the obesity epidemic. Children and young adults are no exception. With modern lifestyle, traditional cardiovascular risk factors, such as hypertension, obesity, dyslipidemia, insulin resistance, kidney damage, are increasingly present in children leading to premature cardiovascular events in adult life. Cardiovascular risk factor can accelerate naturally progressing atherosclerosis, which should be prevented to facilitate quality and longevity of life. Primary and primordial prevention in the pediatric population are of utmost importance. However, if a cardiovascular risk factor is already present, frequent monitoring of possible development of other cardiovascular risk factors and evaluation of end organ damage should be implemented to intervene in time.

Prediagnosis cardiovascular risk and subsequent myocardial infarction (MI) among lymphoma survivors.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 7564-7564
Author(s):  
Talya Salz ◽  
Emily Craig Zabor ◽  
Peter de Nully Brown ◽  
Susanne Oksbjerg Dalton ◽  
Nirupa Jaya Raghunathan ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Hodgkin Lymphoma ◽  
Hospital Discharge ◽  
Cardiovascular Risk Factor ◽  
Hospital Discharge Register ◽  
Increased Risk ◽  
Lymphoma Survivors

7564 Background: Chest radiation is associated with increased risk of MI among lymphoma survivors. The extent to which pre-existing cardiovascular risk factors also contribute to risk is understudied. We investigated this association among a national population of lymphoma survivors with a full range of cardiovascular risk factors. Methods: Using Danish population-based registries, we identified all adults diagnosed with aggressive non-Hodgkin lymphoma or Hodgkin lymphoma from 2000-2010 and followed them from 1 year after diagnosis through 2016. MI was ascertained from the nationwide Hospital Discharge Register and Cause of Death Register. Cardiovascular risk factors (hypertension, dyslipidemia, and diabetes), vascular disease, and intrinsic heart disease prevalent at lymphoma diagnosis were ascertained algorithmically using the National Prescription Register and the Hospital Discharge Register. Controlling for age, sex, histology, receipt of chest radiation, and prevalent cardiovascular diseases, we used multivariable Cox regression to test the association between pre-existing cardiovascular risk factors and subsequent MI. Results: Among 4246 survivors of lymphoma, median age at diagnosis was 60 (interquartile range 45-70 years); median follow-up was 6.9 years (range 0-16 years). 115 survivors were diagnosed with MI. Before lymphoma diagnosis, 28% of survivors had ≥1 cardiovascular risk factor, and 16% of survivors received chest radiation. In multivariable analysis, survivors who received chest radiation had an increased risk of MI compared to survivors who did not (HR=1.92 [95% CI=1.16-3.17]). Survivors with ≥1 cardiovascular risk factor had an increased risk of MI compared to survivors with none (HR = 2.44 [95% CI=1.65-3.62]). Conclusions: In a large, well-characterized, nationally representative study of contemporarily treated lymphoma survivors, prevalent hypertension, dyslipidemia, and diabetes were associated with later MI. Findings suggest that pre-existing cardiovascular risk factors confer the same amount of MI risk as does chest radiation. To prevent MI among survivors, decisions about post-treatment monitoring should address prevalent cardiovascular risk.

Sign in / Sign up

Export Citation Format

Share Document